The temporary softening or loss of the sense of a separate self during a psychedelic experience. Measurable on the Ego-Dissolution Inventory (EDI) and correlated with therapeutic outcomes in depression, addiction, and end-of-life anxiety trials. Driven by 5-HT2A agonism and reduced default mode network activity. Related to — but not identical with — the pop term "ego death": ego dissolution is a graded, commonly reported feature of a full-dose session; ego death is the extreme end of that spectrum.
Ego dissolution is the temporary softening or loss of the sense of a separate self during a psychedelic experience. It is a graded effect, usually appearing at moderate-to-high doses of psilocybin (roughly 20–30 mg pure psilocybin, or ~3g+ dried cubensis). People often describe a feeling of merging with the room, the music, other people, or "everything at once." The effect is measurable: clinical trials use the Ego-Dissolution Inventory (EDI, Nour et al., 2016) and the related Mystical Experience Questionnaire (MEQ-30).
Neurally, ego dissolution tracks with 5-HT2A receptor agonism in the cortex and with reduced activity and connectivity in the default mode network (DMN) — the circuit most tied to the narrative self. fMRI and MEG studies (Carhart-Harris et al.; Imperial College London) show that the deeper the DMN disintegration, the stronger the reported ego dissolution.
Clinically, stronger ego dissolution during a session correlates with larger and more durable reductions in depression, addiction, and end-of-life anxiety symptoms — making it one of the best-established predictors of therapeutic outcome in psychedelic research.
Related to but distinct from ego death: ego dissolution is a common, often partial feature of a full-dose session; ego death is the extreme end of that spectrum, where the ordinary sense of self disappears entirely for a period of time.
See: Psilocybin Therapy (/guides/psilocybin-therapy), Default Mode Network (/glossary/default-mode-network), Ego Death (/glossary/ego-death).
Ego dissolution is one of the strongest predictors of therapeutic benefit in psilocybin trials — more than dose alone. Understanding it helps clients prepare, helps facilitators read the session, and helps researchers interpret outcomes.